{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:39:03Z","timestamp":1761183543553,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.dmpk.2023.100541","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T02:06:57Z","timestamp":1702260417000},"page":"100541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Quantification of fluticasone propionate in human plasma by LC\u2013MS\/MS and its application in the pharmacokinetic study of nasal spray at clinical doses"],"prefix":"10.1016","volume":"54","author":[{"given":"Aya","family":"Yamagata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rena","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6039-2953","authenticated-orcid":false,"given":"Akitomo","family":"Yokokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3614-9328","authenticated-orcid":false,"given":"Tomomi","family":"Furihata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9062-7370","authenticated-orcid":false,"given":"Hiromi","family":"Shibasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2023.100541_bib1","first-page":"485","article-title":"Epidemiological survey of allergic rhinitis in Japan 2019","volume":"123","author":"Matsubara","year":"2020","journal-title":"J\u00a0Otolaryngol Jpn"},{"key":"10.1016\/j.dmpk.2023.100541_bib2","first-page":"109","article-title":"Overcoming barriers to intranasal corticosteroid use in patients with uncontrolled allergic rhinitis","volume":"6","author":"Bridgeman","year":"2017","journal-title":"Integrated Pharm Res Pract"},{"key":"10.1016\/j.dmpk.2023.100541_bib3","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.3928\/19382359-20181212-01","article-title":"Intranasal steroid therapy for allergic rhinitis","volume":"48","author":"Seth","year":"2019","journal-title":"Pediatr Ann"},{"key":"10.1016\/j.dmpk.2023.100541_bib4","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1592\/phco.22.16.1458.33692","article-title":"Intranasal corticosteroids for allergic rhinitis","volume":"22","author":"Trangsrud","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.dmpk.2023.100541_bib5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/thx.52.5.476","article-title":"Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids","volume":"52","author":"Lipworth","year":"1997","journal-title":"Thorax"},{"key":"10.1016\/j.dmpk.2023.100541_bib6","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0091-6749(98)70354-9","article-title":"Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal\u2013axis activity","volume":"101","author":"Wilson","year":"1998","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.dmpk.2023.100541_bib7","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1210\/jc.2015-1218","article-title":"Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis","volume":"100","author":"Broersen","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.dmpk.2023.100541_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1034\/j.1398-9995.2000.00370.x","article-title":"Inhaled and nasal corticosteroids: safety aspects","volume":"55","author":"Passalacqua","year":"2000","journal-title":"Allergy"},{"key":"10.1016\/j.dmpk.2023.100541_bib9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jpba.2011.11.018","article-title":"A\u00a0rapid and sensitive HPLC\u2013APCI-MS\/MS method determination of fluticasone in human plasma: application for a bioequivalency study in nasal spray formulations","volume":"61","author":"Byrro","year":"2012","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.dmpk.2023.100541_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpba.2016.12.008","article-title":"Simultaneous analysis of glucocorticosteroid fluticasone propionate and its metabolite fluticasone propionate 17\u03b2-carboxylic acid in human plasma by UPLC\u2013MS\/MS at sub pg\/mL level","volume":"135","author":"Nair","year":"2017","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.dmpk.2023.100541_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1365-2125.2001.01325.x","article-title":"Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations","volume":"51","author":"Daley-Yates","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2023.100541_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0731-7085(99)00246-0","article-title":"A\u00a0sensitive LC\u2013MS\/MS method for the quantification of fluticasone propionate in human plasma","volume":"22","author":"Krishnaswami","year":"2000","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.dmpk.2023.100541_bib13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jchromb.2008.10.034","article-title":"Investigation of interaction between salmeterol and fluticasone propionate and its effect on quantitative accuracy of an LC\/MS\/MS assay in human plasma at low pg\/mL concentrations","volume":"876","author":"Carter","year":"2008","journal-title":"J\u00a0Chromatogr, B: Anal Technol Biomed Life Sci"},{"key":"10.1016\/j.dmpk.2023.100541_bib14","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1255\/ejms.1044","article-title":"A\u00a0high-throughput liquid chromatography tandem mass spectrometry method for the comparative determination of fluticasone propionate by reversed-phase liquid chromatography and capillary electrophoresis methods in pharmaceutical nasal sprays","volume":"15","author":"da Silva Sangoi","year":"2009","journal-title":"Eur J Mass Spectrom"},{"key":"10.1016\/j.dmpk.2023.100541_bib15","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/chromsci\/48.8.641","article-title":"Determination of fluticasone propionate in nasal sprays by a validated stability-indicating MEKC method","volume":"48","author":"da Silva Sangoi","year":"2010","journal-title":"J\u00a0Chromatogr Sci"},{"key":"10.1016\/j.dmpk.2023.100541_bib16","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/bmc.1708","article-title":"Development of a sensitive method for simultaneous determination of fluticasone propionate and salmeterol in plasma samples by liquid chromatography-tandem mass spectrometry","volume":"26","author":"Silvestro","year":"2012","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.dmpk.2023.100541_bib17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4155\/bio.12.338","article-title":"Ultrasensitive and automated 1 pg\/ml fluticasone propionate assay in human plasma using LC\u2013MS\/MS","volume":"5","author":"Ji","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.dmpk.2023.100541_bib18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jchromb.2006.12.030","article-title":"Systematic and comprehensive strategy for reducing matrix effects in LC\/MS\/MS analyses","volume":"852","author":"Chambers","year":"2007","journal-title":"J\u00a0Chromatogr, B: Anal Technol Biomed Life Sci"},{"key":"10.1016\/j.dmpk.2023.100541_bib19","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00216-011-5164-3","article-title":"Analysis of urinary estrogens, their oxidized metabolites, and other endogenous steroids by benchtop orbitrap LCMS versus traditional quadrupole GCMS","volume":"401","author":"Franke","year":"2011","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.dmpk.2023.100541_bib20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1046\/j.1365-2125.1996.36110.x","article-title":"Pharmacokinetics of intravenous fluticasone propionate in healthy subjects","volume":"41","author":"Mackie","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2023.100541_bib21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0731-7085(99)00213-7","article-title":"An improved method for the determination of fluticasone propionate in human plasma","volume":"21","author":"Laugher","year":"1999","journal-title":"J\u00a0Pharm Biomed Anal"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436723000538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436723000538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:57:27Z","timestamp":1761163047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436723000538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":21,"alternative-id":["S1347436723000538"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2023.100541","relation":{},"ISSN":["1347-4367"],"issn-type":[{"type":"print","value":"1347-4367"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantification of fluticasone propionate in human plasma by LC\u2013MS\/MS and its application in the pharmacokinetic study of nasal spray at clinical doses","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2023.100541","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100541"}}